Executive Director, Global HEOR
Karyopharm Therapeutics
David Ray is currently the Head of Global HEOR at Karyopharm Therapeutics. He focuses on real world evidence strategy for selinexor in patients with relapse/refractory multiple myeloma. Prior to Karyopharm Therapeutics, he worked in similar roles at Novartis Oncology, Ipsen Biopharmaceutics and Epizyme. David is a pharmacist by training and holds advanced degrees in business administration and public health.